The disease control rate, including stable disease, was 91.9% in laBCC and 92.3% in mBCC.532 In addition to BCC, many clinical trials have been performed to evaluate the efficacy of these two agents in the treatment of various tumors, including rare tumors.533–536 Glasdegib is also a selective HH pathway inhibitor that binds to SMO. The gene discussed is SMO; the disease is skin basal cell carcinoma.